Log in to save to my catalogue

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete...

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_808460089

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

About this item

Full title

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

Publisher

England: Elsevier Ltd

Journal title

The lancet oncology, 2010-11, Vol.11 (11), p.1029-1035

Language

English

Formats

Publication information

Publisher

England: Elsevier Ltd

More information

Scope and Contents

Contents

Summary Background Imatinib treatment significantly improves survival in patients with chronic myeloid leukaemia (CML), but little is known about whether treatment can safely be discontinued in the long term. We aimed to assess whether imatinib can be discontinued without occurrence of molecular relapse in patients in complete molecular remission (...

Alternative Titles

Full title

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_808460089

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_808460089

Other Identifiers

ISSN

1470-2045

E-ISSN

1474-5488

DOI

10.1016/S1470-2045(10)70233-3

How to access this item